Lotus Pharmaceutical Co (美時化學製藥), which makes and distributes oral and injected medicine, yesterday said its future parent company Alvogen Inc spent US$187 million to acquire South Korean-based Dream Pharma Ltd, which is to be put under Lotus’ control once the deal is approved.
The US-based Alvogen, which makes generic drugs and biosimilars, plans to acquire the company through its South Koran subsidiary Kunwha Pharmaceutical Co, and the deal is still pending approval from the South Korean government, Lotus said.
Alvogen expects the deal to be completed in the fourth quarter of this year. The deal would make Kunwha the largest generic drug maker in South Korea, Lotus said.
The acquisition should strengthen Kunwha’s retail routes in South Korea and increase Kunwha’s product portfolio because the two companies sell different products, and Alvogen is set to sell its products to Taiwan and other markets in Asia using Alvogen’s networks, Lotus said.
“[The Asia-Pacific region] is one of the fastest-growing regions globally for generic pharmaceuticals. The market remains very fragmented, which provides an excellent opportunity for Alvogen to play a leading role in further industry consolidation,” Alvogen said in its statement yesterday.
Dream Pharma, a subsidiary of Hanwha Chemical Corp, which makes polyethylene, polyvinyl chloride plasticizer and base chemicals, reported revenue of about US$100 million last year, with 56 percent of that from sales of weight-loss drugs, Lotus said.
With 100 drugs currently in the pipeline, Dream Pharma accounts for 35 percent of the South Korean weight-loss drug market, according to Lotus.
“Dream Pharma is not a core business for Hanwha, and we believe we can increase its profit by adjusting Dream Pharma’s structure after acquiring it,” Lotus vice president Hung Yao-le (洪堯樂) said by telephone yesterday.
Alvogen is to spend US$200 million to acquire 67 percent of Lotus’ shares on Aug. 12, and Lotus also plans to spend US$180 million to seize 100 percent of South Korea-based Alvogen Korea and other Asian subsidiaries of Alvogen, Lotus said.
After Lotus acquired Alvogen Korea, Lotus would have a 67 percent stake in Kunwha, which posted a revenue of about US$80 million last year, Lotus said.
Both Dream Pharma and Kunwere in the black for last year, Hung said.
After several years flying high as Asia’s best Nvidia Corp proxy, Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) is increasingly vying with other artificial intelligence (AI) stocks for investor attention. Stock traders are chasing a wider array of beneficiaries as mainstream usage of AI creates demand for hardware beyond the most-advanced chips TSMC makes for Nvidia. Subthemes from the deepening memory crunch to advances in robotics are also luring bids. At the same time, investment caps on single stocks are pushing funds to diversify, while retail investors long familiar with TSMC through its US depositary receipts are being offered a broader set of
UNDER MICROSCOPE: Taiwan detained three people who allegedly conspired to buy servers in Taiwan and export them using fraudulent documentation, prosecutors said Nvidia Corp chief executive officer Jensen Huang (黃仁勳) on Saturday urged Super Micro Computer Inc to tighten up on compliance after Taiwan detained three people this week for allegedly making fraudulent declarations about artificial intelligence (AI) servers made by its US partner. The development marked the nation’s first crackdown on semiconductor smuggling, which grew after the US slapped restrictions on exports of high-end chips such as Nvidia AI accelerators to China. Nvidia is “rigorous” in explaining regulations to all of its partners, Huang told reporters after arriving in Taipei. “Ultimately Super Micro has to run their own company,” he said in response to
TECH RELIANCE: Growth is increasingly reflecting an unequal K-shaped distribution, where technology sectors outperform and other industries struggle, an expert said Standard Chartered Bank has significantly raised its forecast for Taiwan’s economic growth to 9.5 percent this year, up from 7.6 percent previously, citing surging artificial intelligence (AI) demand driving exports, semiconductor production and investment. The upgrade reflects a sustained AI supercycle that continues to fuel demand for advanced chips and technology infrastructure, which form the backbone of Taiwan’s exports, the bank said in a report this week. “We raise our 2026 growth forecast to reflect a much stronger-than-expected first-quarter GDP figure,” Standard Chartered senior economist for greater China and Asia Tommy Wu (胡東安) said in the report. Driven largely by a 35.3 percent
Two of Taiwan’s international carriers, Starlux Airlines Co (星宇航空) and EVA Airways Corp (長榮航空), have retained the five-star airline rating awarded by international airline review organization Skytrax. Starlux was awarded the distinction for a second consecutive year, while EVA Air received it for the 11th straight year, Skytrax said in statements released yesterday and on Thursday last week, respectively. The five-star rating is considered one of the airline industry's highest honors and is awarded following professional audits of airline product and frontline service standards, Skytrax said. The ratings are based on in-depth assessments using unified global quality standards rather than customer review scores
RSS